Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
0(0%)
Results Posted
67%(6 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_1
5
42%
Ph phase_2
6
50%

Phase Distribution

5

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
5(45.5%)
Phase 2Efficacy & side effects
6(54.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(9)
Terminated(1)
Other(2)

Detailed Status

Completed9
unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
90.0%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (45.5%)
Phase 26 (54.5%)

Trials by Status

completed975%
terminated18%
unknown217%

Recent Activity

0 active trials
Showing 5 of 12
completedphase_2

LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.

NCT02450903
completedphase_1

Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer

NCT01772797
completedphase_1

Effect of Hepatic Impairment on LDK378 Pharmacokinetics

NCT01950481
completedphase_1

Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

NCT01634763
completedphase_2

A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer

NCT02276027
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT02450903Phase 2

LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.

Completed
NCT01772797Phase 1

Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer

Completed
NCT01950481Phase 1

Effect of Hepatic Impairment on LDK378 Pharmacokinetics

Completed
NCT01634763Phase 1

Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

Completed
NCT02276027Phase 2

A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer

Completed
NCT01947608

Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

Unknown
NCT01685138Phase 2

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

Completed
NCT01283516Phase 1

A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

Completed
NCT02040870Phase 1

LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Completed
NCT01964157Phase 2

An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement

Unknown
NCT02374489Phase 2

A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma

Terminated
NCT01685060Phase 2

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12